Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GuangYuYuan Chinese Herbal Medicine Co (SHSE:600771) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
GuangYuYuan Chinese Herbal Medicine Co EBITDA Margin % Related Terms
GuangYuYuan Chinese Herbal Medicine Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GuangYuYuan Chinese Herbal Medicine Co EBITDA Margin % Chart
GuangYuYuan Chinese Herbal Medicine Co Annual Data
SHSE:600771 vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, GuangYuYuan Chinese Herbal Medicine Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GuangYuYuan Chinese Herbal Medicine Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GuangYuYuan Chinese Herbal Medicine Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where GuangYuYuan Chinese Herbal Medicine Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GuangYuYuan Chinese Herbal Medicine Co (SHSE:600771) has a EBITDA Margin % of 15.45% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GuangYuYuan Chinese Herbal Medicine Co and its competitors. This is 37% above median its historical median of 11.27. According to the industry distribution chart, GuangYuYuan Chinese Herbal Medicine Co ranks #587 out of 961 companies in the Drug Manufacturers industry, placing it in the top 61.1%.
Is GuangYuYuan Chinese Herbal Medicine Co's EBITDA Margin % too high?
GuangYuYuan Chinese Herbal Medicine Co's current EBITDA Margin % of 15.45% is 37% above median its 10-year median of 11.27. The Drug Manufacturers industry median EBITDA Margin % is 12.49. GuangYuYuan Chinese Herbal Medicine Co's value of 15.45% is 23.7% above this industry median. Based on the distribution chart, GuangYuYuan Chinese Herbal Medicine Co ranks #587 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, GuangYuYuan Chinese Herbal Medicine Co has a GF Score™ of 52/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GuangYuYuan Chinese Herbal Medicine Co's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GuangYuYuan Chinese Herbal Medicine Co ranks #587 out of 961 companies for EBITDA Margin %. This places GuangYuYuan Chinese Herbal Medicine Co in the lower half of its industry. The industry median EBITDA Margin % is 12.49. GuangYuYuan Chinese Herbal Medicine Co's value of 15.45% is 23.7% above this benchmark. While the company's 10-year median is 11.27 vs. the industry median of 12.49, GuangYuYuan Chinese Herbal Medicine Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GuangYuYuan Chinese Herbal Medicine Co's current EBITDA Margin % of 15.45% is 23.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GuangYuYuan Chinese Herbal Medicine Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GuangYuYuan Chinese Herbal Medicine Co's current EBITDA Margin % is 15.45%, which is 37% above median its own 10-year median of 11.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GuangYuYuan Chinese Herbal Medicine Co stock overvalued right now?
Based on GuruFocus' analysis, GuangYuYuan Chinese Herbal Medicine Co (SHSE:600771) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥24.06, compared to a current price of ¥15.04 — trading 37.5% below its estimated fair value. The current EBITDA Margin % is 15.45%, which is 37% above median its 10-year median of 11.27 and 23.7% above the Drug Manufacturers industry median of 12.49. GuangYuYuan Chinese Herbal Medicine Co's overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For GuangYuYuan Chinese Herbal Medicine Co (SHSE:600771), the current EBITDA Margin % is 15.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GuangYuYuan Chinese Herbal Medicine Co (SHSE:600771) Overvalued in 2026?
Based on GuruFocus' analysis, GuangYuYuan Chinese Herbal Medicine Co stock appears to be undervalued.
The current stock price of ¥15.04 is trading 37.5% below its estimated GF Value™ of ¥24.06.
GuruFocus considers GuangYuYuan Chinese Herbal Medicine Co to be Significantly Undervalued.
Key valuation signals for SHSE:600771:
EBITDA Margin %: 15.45% (37% above median its 10-year median of 11.27)
GF Value™: ¥24.06 vs. price of ¥15.04 (37.5% below fair value)
Industry Position: 23.7% above the Drug Manufacturers median (#587 of 961)
No single metric tells the full story. See the SHSE:600771 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GuangYuYuan Chinese Herbal Medicine Co Business Description
GuangYuYuan Chinese Herbal Medicine Co Ltd distributes pharmaceutical products. Its products include far plate turtle age wine bottle, niuhuang qingxin pills, boutique angong niuhuang wan, modified turtle age wine, ding kundan, and many more.
52GF Score
Get the complete analysis for SHSE:600771
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600771 has been successfully added to your 
